A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

In 2021, the Food and Drug Administration (FDA) approved the brand-name version of semaglutide, Wegovy, for chronic weight management in adults with obesity or overweight. The FDA noted that ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Medications that have transformed the treatment of obesity may also help people drink less alcohol ... The new study looked ...

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.